Bio Vantage

Amgen: Equity Report And Stock Valuation

Executive Summary

Amgen (NASDAQ:AMGN) is among the largest global biotechnology companies, with a $68B market cap and over $15.5B in combined sales in 2011. Our research shows that Amgen will have significant revenue growth from several key drugs that have been approved since 2006. As AMGN's current stock price is ~$88, we believe that the stock is currently slightly undervalued, and trading at a 10% discount compared to its fair value of $96.

Amgen has had several transformations in its business model that have driven its stock price upwards since 2011. The key drivers for its revenues come from Prolia and Xgeva, both approved in 2011 for the treatment and prevention of osteoporosis. There is significant upside potential

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details